Table 1.
Baseline Characteristics of Study Population
| Subject characteristicsa | CrPic (n = 33) | Placebo (n = 30) |
|---|---|---|
| Demographics | ||
| Age, years | 47.7 ± 10 | 51.1 ± 13 |
| Male sex, n | 13 | 18 |
| Female sex, n | 20 | 12 |
| Race | ||
| White, n | 16 | 27 |
| Non-white, n | 17 | 3 |
| Current smokers, n | 4 | 6 |
| Current ethanol users, n | 22 | 20 |
| Metabolic syndrome features | ||
| Waist circumference, cm | 109 ± 13 | 112 ± 13 |
| Men | 116 ± 8 | 119 ± 15 |
| Women | 105 ± 15 | 104 ± 13 |
| Fasting TG mmol/L | 2.0 ± 1 | 2.1 ± 0.8 |
| Fasting HDL-C mmol/L | 1.03 ± 0.2 | 1.04 ± 0.2 |
| Men | 0.97 ± 0.2 | 0.97 ± 0.2 |
| Women | 1.06 ± 0.2 | 1.15 ± 0.2 |
| Systolic blood pressure, mmHg | 130 ± 12 | 129 ± 15 |
| Diastolic blood pressure, mmHg | 81 ± 10 | 79 ± 10 |
| Fasting glucose, mmol/L | 4.74 ± 0.8 | 4.54 ± 0.6 |
| Impaired fasting glucose, n | 4 | 2 |
| Impaired glucose tolerance, n | 14 | 13 |
| Body mass index, kg/m2 | 37.8 ± 9 | 35.2 ± 6 |
| Percent body fat | 39.9 ± 12 | 36.7 ± 11 |
| Use of antihypertensive drugs, n (%) | 22 (66.7) | 17 (56.7) |
| Use of statin drugs | 8 | 12 |
| Glucose metabolism measures | ||
| SI (mU/L)1min−1 | 2.20 ± 2.7 | 1.68 ± 1.1 |
| Sg min−1 | 0.02 ± 0.01 | 0.08 ± 0.3 |
| AIRg mUL−1 | 653 ± 557 | 806 ± 505 |
| DI | 1294 ± 1620 | 1312 ± 1144 |
a
All values are mean ± SD; comparisons nonsignificant except for race, P < 0.001.
Abbreviations: CrPic, chromium picolinate; TG, triglycerides; HDL-C, high-density lipoprotein cholesterol; SI, insulin sensitivity; Sg, glucose effectiveness index; AIRg, acute insulin response to glucose; DI, disposition index.